BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

China Kanghui Holdings Reports Second Quarter 2012 Financial Results


8/22/2012 10:18:41 AM

CHANGZHOU, China, Aug. 21, 2012 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH) ("Kanghui" or the "Company"), a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced its unaudited financial results for the second quarter of 2012.

Second Quarter 2012 Highlights

  • Total net revenue for the second quarter of 2012 increased by 23.6% year-over-year to RMB101.1 millionfrom RMB81.8 million in the corresponding period of the prior year.
  • Gross profit for the second quarter of 2012 increased by 24.0% year-over-year to RMB71.9 million from RMB58.0 million in the corresponding period of the prior year.
  • Operating income for the second quarter of 2012 increased by 27.3% year-over-year to RMB38.7 millionfrom RMB30.4 million in the corresponding period of the prior year.
  • Net income attributable to Kanghui for the second quarter of 2012 increased by 24.7% year-over-year to RMB34.8 million from RMB27.9 million in the corresponding period of the prior year.
  • Non-GAAP[1] net income for the second quarter of 2012 increased by 33.0% year-over-year to RMB39.1 million from RMB29.4 million in the corresponding period of the prior year.

Mr. Libo Yang, Chief Executive Officer of the Company, stated, "We are delighted that Kanghui's second quarter marked another strong performance. Growth from trauma and spine sales remained robust, and we further expanded our product offerings by launching our joint reconstruction product into the international markets, while adding another new spine product exclusively marketed in China. Domestic sales were strong, as we continued to gain momentum throughout China. With unabated strong demand and promising new product launches, we believe we are well positioned for sustained success going forward."

Ms. Sarah Wang, Chief Financial Officer of Kanghui, commented, "I am proud that Kanghui delivered our eighth consecutive strong quarter since its initial public offering, with our first-ever quarter of recording over RMB 100 million in net revenue. Our outstanding growth in net revenue, along with double-digit growth in key operating metrics, exemplify the strength of our business model. Benefiting from the strong domestic sales of our proprietary products, our gross profit margins continued to exceed expectations, and as we build on this positive momentum, we are incrementally more confident in outlook for the remainder of 2012."

Second Quarter 2012 Financial and Operating Results

Net revenue increased by 23.6% year-over-year to RMB101.1 million ($15.9 million)[2] in the second quarter of 2012 from RMB81.8 million in the corresponding period of the prior year.

Net revenue by product category:

Net revenue from trauma products increased by 25.3% year-over-year to RMB59.5 million ($9.4 million) in the second quarter of 2012 from RMB47.5 million in the corresponding period of the prior year. Net revenue from spine products increased by 24.3% year-over-year to RMB32.7 million ($5.1 million) in the second quarter of 2012 from RMB26.3 million in the corresponding period of the prior year. Net revenue from OEM products increased by 11.3% year-over-year to RMB8.9 million ($1.4 million) in the second quarter of 2012 from RMB8.0 million in the corresponding period of the prior year. Joint Reconstruction products initialed sales in June, and generated net revenue of RMB102,000($16,000) in the second quarter of 2012.

Net revenue by geographic markets:

Domestic sales of proprietary products increased by 34.7% year-over-year to RMB77.6 million ($12.2 million) in the second quarter of 2012 from RMB57.6 million in the corresponding period of the prior year, while international sales of proprietary products decreased by 8.7% year-over-year to RMB14.7 million ($2.3 million) in the second quarter of 2012 from RMB16.1 million in the corresponding period of the prior year. The decrease in international sales was primarily attributable to the Company's strategic shift in production to fulfill the strong domestic orders, as well as lower sales in the Middle East due to the region's political instability.

In the second quarter of 2012, cost of revenue increased by 23.2% year-over-year to RMB29.2 million ($4.6 million) from RMB23.7 million in the corresponding period of the prior year. Gross profit increased by 24.0% year-over-year to RMB71.9 million ($11.3 million) in the second quarter of 2012 from RMB58.0 million in the corresponding period of the prior year. Gross margin for the second quarter of 2012 was 71.1%, compared to 71.0% in the corresponding period of the prior year.

Selling expenses decreased by 1.7% year-over-year to RMB11.6 million ($1.8 million) in the second quarter of 2012 from RMB11.8 million in the corresponding period of the prior year. General and administrative expenses increased by 28.4% year-over-year to RMB18.1 million ($2.8 million) in the second quarter of 2012 from RMB14.1 million in the corresponding period of the prior year. Research and development expenses increased by 88.9% year-over-year to RMB3.4 million ($0.5 million) in the second quarter of 2012 from RMB1.8 million in the corresponding period of the prior year.

Operating income increased by 27.3% year-over-year to RMB38.7 million ($6.1 million) in the second quarter of 2012 from RMB30.4 million in the corresponding period of the prior year. Operating margin increased to 38.3% in the second quarter of 2012 from 37.2% in the corresponding period of the prior year.

Income tax expense in the second quarter of 2012 was RMB6.5 million ($1.0 million), representing an effective tax rate of 15.8%, compared to an income tax expense of RMB3.8 million, and an effective tax rate of 12.0% in the corresponding period of the prior year.

Net income attributable to China Kanghui Holdings was RMB34.8 million ($5.5 million) in the second quarter of 2012, representing a year-over-year increase of 24.7% from RMB27.9 million in the corresponding period of the prior year. On a diluted per ADS[3] basis, the Company reported net income per diluted ADS of RMB1.33($0.21) in the second quarter of 2012, compared to a net income per diluted ADS of RMB1.09 in the corresponding period of the prior year.

Non-GAAP net income, which excludes share-based compensation expenses, increased by 33.0% to RMB39.1 million ($6.2 million) from RMB29.4 million in the corresponding period of the prior year. The Company reported non-GAAP net income per diluted ADS of RMB1.50($0.24) in the second quarter of 2012, compared to a non-GAAP net income per diluted ADS of RMB1.11 in the corresponding period of the prior year.

During the second quarter of 2012, the Company had a weighted average diluted share count of 156.3 million shares (equivalent to 26.1 million ADSs), compared to 153.7 million shares (equivalent to 25.6 million ADSs) in the corresponding period of the prior year.

Balance Sheet

As of June 30, 2012, the Company had cash and cash equivalents of RMB432.1 million ($68.0 million), compared to RMB380.1 million as of December 31, 2011. As of June 30 2012, the Company held short-term investments of RMB10.3 million ($1.6 million), compared to RMB77.0 million as of December 31, 2011.

Business Outlook

Mr. Yang added, "Our solid performance in the first half of 2012 and the recent successful new product launches have set the stage for continued success in the remainder of 2012, providing us with greater comfort in our top line forecast. Moreover, reflecting on our strong gross margins and continuing discipline in optimizing operations and controlling overhead costs, we are slightly raising our full year 2012 guidance for Non-GAAP net income."

The Company narrows its total net revenue outlook for full year 2012 to be in the range of RMB395 million to RMB403 million, which represents year-over-year growth of 20.8% to 23.3%. The Company raises its full year 2012 non-GAAP net income to a range of RMB149 million to RMB154 million, from its prior expectation of RMB146 million to RMB153 million.

This guidance is based on the current market conditions and reflects the Company's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.

Non-Cash Share-Based Compensation Expenses

The Company recognized non-cash share-based compensation expenses of RMB4.4 million ($0.7 million) in the second quarter of 2012.

The Company classified these non-cash share-based compensation expenses in its costs of revenue, selling expenses, general and administrative expenses as well as in research and development expenses. The break out of these expenses per line item is provided in the financial tables attached to this press release.

The Company has provided a non-GAAP presentation of results, which excludes the non-cash share-based compensation expenses. Please refer to the non-GAAP presentation provided in the appendix for a year-over-year comparison of non-cash share-based compensation expenses. The Company believes that this non-GAAP presentation is a helpful tool for the Company to plan and forecast future periods and both management and investors benefit from referring to such non-GAAP presentation in assessing the performance of the Company.

Conference Call

Kanghui will hold a corresponding conference call and live webcast at 8:00 a.m. ET (8:00 p.m. Beijing Time) on Wednesday, August 22, 2012 to discuss second quarter 2012 results and answer questions from investors. Listeners may access the call by dialing:

US Toll Free:

1-866-519-4004

US Toll/International:

1-718-354-1231

Hong Kong Toll Free:

800-930-346

Hong Kong Toll:

852-2475-0994

China Toll Free:

800-819-0121

China Toll Free (Mobile):

400-620-8038

Conference ID:

12464049

A replay of the webcast will be accessible through August 29, 2012 on http://ir.kanghui.com or by dialing:

United States toll free:

1-866-214-5335

US Toll/International:

1-718-354-1232

Passcode:

12464049

About China Kanghui Holdings

Founded in 1997, Kanghui is a leading domestic developer, manufacturer and marketer of orthopedic implants in China. The Company offers a wide array of proprietary orthopedic implant products in trauma, spine and joint reconstruction, and has an extensive nationwide network of distributors for its products in China, as well as in 29 other countries, as of June, 30, 2012. Kanghui has strong research and development capabilities, focused on developing new proprietary products and product lines, and enhancing existing products and product lines. For more information, please visit www.kanghui.com.

Use of Non-GAAP Financial Measures

The Company has included non-GAAP financial measures in this press release. Non-GAAP financial measures are defined as GAAP gross profit excluding non-cash share-based compensation expenses, operating income excluding non-cash share-based compensation expenses, net income excluding non-cash share-based compensation expenses, net margin excluding non-cash share-based compensation expenses, basic earnings per share and per ADS excluding non-cash share-based compensation expenses, and diluted earnings per share and per ADS excluding non-cash share-based compensation expenses. The Company believes that management and investors benefit from referring to the non-GAAP financial measures in assessing the performance of the Company and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. The use of non-GAAP financial measures has limitations and readers should not consider non-GAAP financial measures in isolation from or as alternatives to consolidated financial metrics prepared in accordance with U.S. GAAP. Readers are encouraged to refer to the reconciliation of non-GAAP measures to GAAP measures included herein.

Safe-Harbor Statement

This press release contains statements of a forward-looking nature, including, among other things, the Company's unaudited operating results for 2012, expected new product introductions, the demand for orthopedic products in China, future prospects of the Company and the ability for the Company to realize its business plans for 2012. These forward-looking statements are not historical facts but instead represent only the Company's belief regarding expected results and events, many of which, by their nature, are inherently uncertain and outside of the Company's control. The actual results and other circumstances of the Company may differ, possibly materially, from the anticipated results and events indicated in these forward-looking statements. Announced results for the second quarter of 2012 are preliminary, unaudited and subject to audit adjustment. Adjustments to the financial statements may be identified when audit work is performed for the year-end audit, which could result in significant differences from this preliminary unaudited financial information. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as "may," "could," "would," "plan," "anticipate," "believe," "estimate," "predict," "potential," "expects," "intends" and "future" or similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management's current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company's control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including the Company's beliefs regarding its strengths and strategies; the Company's ability to expand its international business; the Company's ability to develop and successfully market new products in China and internationally; the Company's current expansion strategy, including its ability to expand its manufacturing and research and development facilities and capabilities and the Company's future prospects, business development, results of operations and financial condition. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's annual report on Form 20-F for the fiscal year 2011, as filed with the Securities and Exchange Commission on April 30, 2012, and are available on the Securities and Exchange Commission's website at www.sec.gov. For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations, and prospects, please see "Risk Factors" that begins on page 6 of the Company's annual report for fiscal year 2011 and in documents subsequently filed by the Company from time to time with the Securities and Exchange Commission, which can be found on the Company's website at www.kanghui.com or at www.sec.gov.

Investor Relations Contact Information

Asia Bridge Capital Limited
Wendy Sun
Tel: 86-10-8556-9033 (China)
1-888-321-2558 (U.S.)
Email: wendy.sun@asiabridgegroup.com

China Kanghui Holdings

Summary - SecondQuarter of 2012

(RMB in thousands, except for per share data and per ADS data)






Three Months Ended
June 30,


Six Months Ended
June 30,


2011

2012


2011

2012


Unaudited

Unaudited


Unaudited

Unaudited



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES